Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models

Abstract A6: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach

(2014) Jaeyeon Kim et al.   CANCER RESEARCH

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

(2013) Ignace B. Vergote et al.   JOURNAL OF CLINICAL ONCOLOGY

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

(2013) Ahmad Awada et al.   LANCET ONCOLOGY

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

(2012) Razelle Kurzrock et al.   CANCER

Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors

(2012) Jeffrey R. Infante et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

(2012) G. S. Jameson et al.   CLINICAL CANCER RESEARCH

Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

(2011) Twan Lammers et al.   JOURNAL OF CONTROLLED RELEASE

Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect

(2010) Yasuhiro Matsumura   ADVANCED DRUG DELIVERY REVIEWS

Phase I Study of NK012, a Novel SN-38-Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors

(2010) T. Hamaguchi et al.   CLINICAL CANCER RESEARCH

PEG conjugates in clinical development or use as anticancer agents: An overview

(2009) Gianfranco Pasut et al.   ADVANCED DRUG DELIVERY REVIEWS

Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11-Refractory Model

(2008) P. Sapra et al.   CLINICAL CANCER RESEARCH

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL